Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Plasma Cell Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 337 (final count)
- Started
- Jun 16, 2020
- Main results expected
- Oct 14, 2030
- Fully finished
- Oct 21, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with Treatment-emergent adverse events (AEs) and serious adverse events- Safety Run-in Part
Measured over: Up to approximately 63 months
Plasma concentration of isatuximab during the treatment period - Safety Run-in Part
Measured over: After first infusion from Cycle 1 Day 1 to Day 28 in safety run-in part
Receptor density/receptor occupancy Safety Run-in Part
Measured over: Baseline to Cycle 2 Day 1 (each cycle is 28 days)
Progression-free survival (PFS) Randomized Phase 3 Part
Measured over: Up to approximately 114 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04270409 · record last updated 2025-12-12 · checked 2026-11-09 15:47 UTC